T-007 (TNK Therapeutics/Celularity)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameT-007 (TNK Therapeutics/Celularity)
Drug Alias NameCAR2 anti-CD38 A2 CAR-T cells (TNK Therapeutics/Cellularity)anti-CD38 CAR T-cell therapy (TNK Therapeutics/Celularity)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTnk Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTnk Therapeutics IncCelularity Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A